Condition: Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer · Sponsor: Alexander B Olawaiye, MD
This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.
This description comes directly from the study's public registry record.
Kelsey Mitch, BSN · 412-648-6417 · adamikka2@upmc.edu
Lucia Borasso, BSN · 412-641-3304 · borrlm@upmc.edu
Always discuss trial participation with your own doctor first.
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05071937